A detailed history of Eagle Bay Advisors LLC transactions in Igm Biosciences, Inc. stock. As of the latest transaction made, Eagle Bay Advisors LLC holds 44,635 shares of IGMS stock, worth $396,805. This represents 0.43% of its overall portfolio holdings.

Number of Shares
44,635
Previous 44,635 -0.0%
Holding current value
$396,805
Previous $306,000 141.18%
% of portfolio
0.43%
Previous 0.19%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 10, 2023

BUY
$8.86 - $14.0 $26,580 - $42,000
3,000 Added 7.21%
44,635 $411,000
Q2 2022

Aug 19, 2022

BUY
$13.27 - $25.5 $90,236 - $173,400
6,800 Added 19.52%
41,635 $751 Million
Q4 2021

Jan 21, 2022

SELL
$27.59 - $66.39 $12,691 - $30,539
-460 Reduced 1.3%
34,835 $1.02 Million
Q3 2021

Nov 12, 2021

BUY
$65.76 - $90.65 $30,249 - $41,699
460 Added 1.32%
35,295 $2.32 Million
Q2 2021

Jul 30, 2021

BUY
$57.98 - $96.6 $2.02 Million - $3.37 Million
34,835 New
34,835 $2.9 Million

Others Institutions Holding IGMS

About IGM Biosciences, Inc.


  • Ticker IGMS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,969,000
  • Market Cap $258M
  • Description
  • IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...
More about IGMS
Track This Portfolio

Track Eagle Bay Advisors LLC Portfolio

Follow Eagle Bay Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eagle Bay Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Eagle Bay Advisors LLC with notifications on news.